Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhizoma Arisaemetis Preparata, known in Traditional Chinese Medicine (TCM) as **Zhi Tian Nan Xing**, is a processed herbal preparation derived from the tubers of *Arisaema* species, such as *Arisaema erubescens*, *Arisaema heterophyllum*, or *Arisaema amurense*. The raw herb is naturally toxic and acrid; therefore, it is typically processed with ginger juice and alum to mitigate toxicity and enhance its therapeutic properties. In clinical research, particularly in China, it is being investigated for transvaginal administration to treat persistent high-risk human papillomavirus (HPV) infections and associated lesions like cervical intraepithelial neoplasia (CIN) and vaginal intraepithelial neoplasia (VaIN). Its mechanism of action is thought to involve the induction of apoptosis in HPV-infected cells and the modulation of the local immune microenvironment, although specific molecular targets are not fully characterized in standard Western pharmacology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rhizoma arisaemetis preparata.